Sermorelin and Sleep: The Slow-Wave Connection

Because GHRH promotes slow-wave sleep, and because both decline with age, researchers asked the obvious question: does giving GHRH to older adults restore deep sleep?

The findings, from a series of studies in the 1990s and 2000s, are consistent in direction and modest in size. In healthy older men, GHRH given at night increased slow-wave sleep and reduced the amount of time awake after falling asleep, alongside the expected rise in growth hormone. In older women the sleep effect was less consistent. The effects on sleep were real on the sleep-lab recordings, and smaller than the effect on hormone levels; participants did not go from broken sleep to the sleep of a twenty-five-year-old.

Sermorelin is GHRH's active fragment, so these studies are the closest evidence there is for its effect on sleep, with two caveats worth being plain about. They used injected GHRH in a laboratory, not the oral tablet we prescribe, and they were small. No large trial has tested sermorelin as a treatment for insomnia in older adults, and we do not describe it as one.

What it plausibly does: restores some of the nightly growth-hormone pulse, and with it some of the slow-wave sleep that the pulse and the signal share. Many people on it describe deeper, more continuous sleep in the first weeks, and the mechanism gives that report a basis beyond placebo — though placebo is powerful for sleep, and we say so.

What it does not do: treat a sleep disorder. It does not open an airway that closes during sleep. It does not fix a circadian rhythm shifted by shift work or screens. It does not address the night-time waking of untreated menopause, or the early waking of depression, or the restlessness of an overactive thyroid. Each of those is a cause with its own treatment, and a peptide that improves deep sleep in a healthy sleeper does nothing for the thing that is actually breaking the night.

That is the reason for the next section.

Poor sleep is a symptom, not a diagnosis, and it is the symptom most often brought to a sermorelin consultation. Before we prescribe, we want to know why the sleep is poor, because the commonest answers in adults over forty are ones sermorelin would mask rather than treat.

Sleep apnea is the one we look hardest for: loud snoring, witnessed pauses, waking unrefreshed, daytime sleepiness, a thick neck, morning headaches. It is under-diagnosed, it is treatable, and it is a condition in which growth-hormone stimulation is not a good idea until the airway is managed. A positive screen goes to a sleep study before anything else — the sleep conditions page sets out the screening we use. Menopausal sleep disruption goes to the women's HRT page, because estrogen and progesterone treat it and a peptide does not. Mood, thyroid and medication causes are asked about and referred where they need to be.

A person whose sleep is poor for a reason that has been found and treated, and who is still sleeping less deeply than they used to, is the one for whom the slow-wave connection is relevant. That is the order.